Clinical Trial

Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-17; most recent amendment 2026-04-17.
Status change: Not Yet Recruiting → Recruiting 2026-01-20
Trial Details
NCT Number NCT07308574
Lead Sponsor Alexion Pharmaceuticals, Inc.
Conditions aHUS, Atypical Hemolytic Uremic Syndrome
Enrollment 20 participants
Start Date 2025-12-19
Primary Completion 2027-06-25 (estimated)
Study Completion 2027-06-25 (estimated)
Updated on ClinicalTrials.gov 2026-04-20